ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) regained the global rights to IMM2510 and IMM27M after terminating a license agreement with Axion Bio, according to a Hong Kong bourse filing Tuesday.
Shares of the firm fell nearly 1% in morning trade Wednesday.
The termination does not affect the $35 million ImmuneOnco received as upfront and milestone payment from Axion, the firm said.
Both drug candidates were being developed as anti-tumor medicines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments